JP2020520677A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020520677A5 JP2020520677A5 JP2020515296A JP2020515296A JP2020520677A5 JP 2020520677 A5 JP2020520677 A5 JP 2020520677A5 JP 2020515296 A JP2020515296 A JP 2020515296A JP 2020515296 A JP2020515296 A JP 2020515296A JP 2020520677 A5 JP2020520677 A5 JP 2020520677A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- ammonia
- hyperammonemia
- glutamine synthetase
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 72
- 239000003795 chemical substances by application Substances 0.000 claims 38
- 229910021529 ammonia Inorganic materials 0.000 claims 36
- 108091006065 Gs proteins Proteins 0.000 claims 27
- 206010020575 Hyperammonaemia Diseases 0.000 claims 27
- 102000005396 glutamine synthetase Human genes 0.000 claims 27
- 108020002326 glutamine synthetase Proteins 0.000 claims 27
- 239000000203 mixture Substances 0.000 claims 26
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 20
- 102000004169 proteins and genes Human genes 0.000 claims 20
- 108090000623 proteins and genes Proteins 0.000 claims 20
- 230000002265 prevention Effects 0.000 claims 19
- 239000013604 expression vector Substances 0.000 claims 17
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- 239000012634 fragment Substances 0.000 claims 11
- 239000002202 Polyethylene glycol Substances 0.000 claims 10
- 229920001223 polyethylene glycol Polymers 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 9
- 239000002516 radical scavenger Substances 0.000 claims 9
- 229940124597 therapeutic agent Drugs 0.000 claims 9
- 238000007911 parenteral administration Methods 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 230000009885 systemic effect Effects 0.000 claims 6
- 239000003638 chemical reducing agent Substances 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 230000004143 urea cycle Effects 0.000 claims 4
- 238000002360 preparation method Methods 0.000 claims 3
- 239000006096 absorbing agent Substances 0.000 claims 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229960003424 phenylacetic acid Drugs 0.000 claims 2
- 239000003279 phenylacetic acid Substances 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 238000007910 systemic administration Methods 0.000 claims 2
- GVNOKKGCPWLUOT-UHFFFAOYSA-N 2-phenylbutanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCC(C(O)=O)C1=CC=CC=C1 GVNOKKGCPWLUOT-UHFFFAOYSA-N 0.000 claims 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 claims 1
- 208000007788 Acute Liver Failure Diseases 0.000 claims 1
- 206010000804 Acute hepatic failure Diseases 0.000 claims 1
- 239000005711 Benzoic acid Substances 0.000 claims 1
- 208000027219 Deficiency disease Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- ITIONVBQFUNVJV-UHFFFAOYSA-N Etomidoline Chemical compound C12=CC=CC=C2C(=O)N(CC)C1NC(C=C1)=CC=C1OCCN1CCCCC1 ITIONVBQFUNVJV-UHFFFAOYSA-N 0.000 claims 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 claims 1
- 241000736262 Microbiota Species 0.000 claims 1
- 206010053159 Organ failure Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 231100000836 acute liver failure Toxicity 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000014509 gene expression Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000003456 ion exchange resin Substances 0.000 claims 1
- 229920003303 ion-exchange polymer Polymers 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 230000008085 renal dysfunction Effects 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 claims 1
- 229960003040 rifaximin Drugs 0.000 claims 1
- 229940006198 sodium phenylacetate Drugs 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023038030A JP7688926B2 (ja) | 2017-05-24 | 2023-03-10 | 高アンモニア血症を治療するためのグルタミン合成酵素の使用 |
| JP2024026784A JP2024059833A (ja) | 2017-05-24 | 2024-02-26 | 高アンモニア血症を治療するためのグルタミン合成酵素の使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1708288.4 | 2017-05-24 | ||
| GBGB1708288.4A GB201708288D0 (en) | 2017-05-24 | 2017-05-24 | Use of glutamine synthetase for treating hyperammonemia |
| GB1800867.2 | 2018-01-19 | ||
| GBGB1800867.2A GB201800867D0 (en) | 2018-01-19 | 2018-01-19 | Use of glutamine synthetase for treating hyperammonemia |
| PCT/GB2018/051415 WO2018215780A1 (en) | 2017-05-24 | 2018-05-24 | Use of glutamine synthetase for treating hyperammonemia |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023038030A Division JP7688926B2 (ja) | 2017-05-24 | 2023-03-10 | 高アンモニア血症を治療するためのグルタミン合成酵素の使用 |
| JP2024026784A Division JP2024059833A (ja) | 2017-05-24 | 2024-02-26 | 高アンモニア血症を治療するためのグルタミン合成酵素の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020520677A JP2020520677A (ja) | 2020-07-16 |
| JP2020520677A5 true JP2020520677A5 (enExample) | 2021-07-26 |
Family
ID=62492675
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020515296A Pending JP2020520677A (ja) | 2017-05-24 | 2018-05-24 | 高アンモニア血症を治療するためのグルタミン合成酵素の使用 |
| JP2023038030A Active JP7688926B2 (ja) | 2017-05-24 | 2023-03-10 | 高アンモニア血症を治療するためのグルタミン合成酵素の使用 |
| JP2024026784A Pending JP2024059833A (ja) | 2017-05-24 | 2024-02-26 | 高アンモニア血症を治療するためのグルタミン合成酵素の使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023038030A Active JP7688926B2 (ja) | 2017-05-24 | 2023-03-10 | 高アンモニア血症を治療するためのグルタミン合成酵素の使用 |
| JP2024026784A Pending JP2024059833A (ja) | 2017-05-24 | 2024-02-26 | 高アンモニア血症を治療するためのグルタミン合成酵素の使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US12359184B2 (enExample) |
| EP (3) | EP4295904A3 (enExample) |
| JP (3) | JP2020520677A (enExample) |
| KR (2) | KR20250093434A (enExample) |
| CN (2) | CN118105471A (enExample) |
| AU (2) | AU2018272294B2 (enExample) |
| BR (1) | BR112019024750A2 (enExample) |
| CA (1) | CA3064352A1 (enExample) |
| IL (1) | IL270817B2 (enExample) |
| MX (2) | MX2019014027A (enExample) |
| WO (1) | WO2018215780A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4295904A3 (en) * | 2017-05-24 | 2024-02-28 | Thoeris GmbH | Use of glutamine synthetase for treating hyperammonemia |
| EP3856231A1 (en) * | 2018-09-28 | 2021-08-04 | Thoeris GmbH | Use of glutamine synthetase for treating fatty liver disease |
| CN110133287B (zh) * | 2019-05-22 | 2021-07-30 | 上海碧云天生物技术有限公司 | 蛋白抽提溶液及其应用 |
| JP2023532939A (ja) | 2020-06-30 | 2023-08-01 | インダストリー－アカデミック コーオペレイション ファウンデーション キョンサン ナショナル ユニバーシティ | チロシンを有効成分として含むタンパク質内のチロシンのニトロ化による疾患の予防、改善または治療用組成物 |
| JP2024168541A (ja) | 2023-05-24 | 2024-12-05 | トヨタ自動車株式会社 | 二次電池 |
| CN118949035A (zh) * | 2024-07-31 | 2024-11-15 | 北京大学第一医院(北京大学第一临床医学院) | Glul生物标志物在心力衰竭诊断、治疗或预后预测中的应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7590493B2 (en) | 2000-07-31 | 2009-09-15 | Ocimum Biosolutions, Inc. | Methods for determining hepatotoxins |
| US6812339B1 (en) | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| US6451547B1 (en) | 2001-04-25 | 2002-09-17 | Syn X Pharma | Process for differential diagnosis of Alzheimer's dementia and device therefor |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| AUPR805101A0 (en) | 2001-10-03 | 2001-10-25 | University Of New South Wales, The | A method of genetic screening using an amplifiable gene |
| JP2003225093A (ja) | 2001-11-30 | 2003-08-12 | Sumitomo Pharmaceut Co Ltd | 軟骨障害マーカー及びその利用 |
| US6875792B2 (en) | 2002-01-31 | 2005-04-05 | Mso Pharma Llc | Dosage form of L-Methionine S-Sulfoximine |
| JP2003274963A (ja) | 2002-03-22 | 2003-09-30 | Japan Science & Technology Corp | 遺伝子組換え細胞株及びそれを用いた肝機能補助装置 |
| US20050074865A1 (en) | 2002-08-27 | 2005-04-07 | Compound Therapeutics, Inc. | Adzymes and uses thereof |
| EP1578996A4 (en) | 2002-10-18 | 2007-12-19 | Genentech Inc | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS |
| CA2503390A1 (en) | 2002-11-01 | 2004-05-21 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US20050255114A1 (en) | 2003-04-07 | 2005-11-17 | Nuvelo, Inc. | Methods and diagnosis for the treatment of preeclampsia |
| WO2004106489A2 (en) | 2003-05-21 | 2004-12-09 | Divergence, Inc | Nematode GS-like sequences |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US20070098702A1 (en) * | 2005-02-17 | 2007-05-03 | University Of Maryland, Baltimore | Recombinant protein polymer vectors for systemic gene delivery |
| EP1752143A1 (en) | 2005-08-08 | 2007-02-14 | NewThera | Novel uses for drugs targeting glutamine synthetase |
| WO2007071339A1 (en) | 2005-12-21 | 2007-06-28 | Universite Catholique De Louvain | Isolated liver stem cells |
| RU2362572C2 (ru) | 2007-07-17 | 2009-07-27 | Юрий Георгиевич Каминский | Способ снижения концентрации аммиака в крови с помощью аммоцитов и инкапсулированной глутаминсинтетазы |
| PL3133396T3 (pl) * | 2008-04-29 | 2019-03-29 | Horizon Therapeutics, Llc | Sposób leczenia z zastosowaniem leków wychwytujących amoniak |
| JP2012501641A (ja) | 2008-09-08 | 2012-01-26 | セレクティス | グルタミンシンセターゼ遺伝子からのｄｎａ標的配列を切断するメガヌクレアーゼ変異型及びその使用 |
| EP2575862A2 (en) | 2010-05-28 | 2013-04-10 | Mind-Nrg Sa | Neuregulin isoforms, neuregulin polypeptides and uses thereof |
| WO2013020914A1 (en) * | 2011-08-10 | 2013-02-14 | Celares Gmbh | Peg-conjugated peptides |
| WO2013137583A1 (en) | 2012-03-12 | 2013-09-19 | Hanwha Chemical Corporation | An expression vector comprising a polynucleotide encoding a modified glutamine synthetase and a method for preparing a target protein employing the same |
| EP2674495A1 (en) | 2012-06-14 | 2013-12-18 | Sanofi | CHO expression system |
| MX377806B (es) | 2014-11-07 | 2025-03-11 | Instituto Nac De Ciencias Medicas Y Nutricion Salvador Zubiran | Uso de un baculovirus recombinante que media la expresión de la glutamina sintetasa para tratar la encefalopatía hepática. |
| NZ732632A (en) * | 2014-11-24 | 2021-07-30 | Ucl Business Ltd | Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies |
| EP3307879A2 (en) * | 2015-06-10 | 2018-04-18 | Synlogic, Inc. | Bacteria engineered to treat diseases associated with hyperammonemia |
| KR102479894B1 (ko) | 2016-03-30 | 2022-12-21 | 스파크 테라퓨틱스, 인코포레이티드 | 재조합 단백질 및/또는 바이러스 벡터 생산용 세포주 |
| EP3452101A2 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
| TWI821905B (zh) | 2016-05-11 | 2023-11-11 | 美商安美基公司 | 使用麩醯胺合成酶基因內互補載體直接選擇表現高水準異質蛋白的細胞 |
| CN110023500B (zh) | 2016-11-16 | 2024-10-11 | 新加坡科技研究局 | 作为选择标记的减毒谷氨酰胺合成酶 |
| EP4295904A3 (en) | 2017-05-24 | 2024-02-28 | Thoeris GmbH | Use of glutamine synthetase for treating hyperammonemia |
| US11479792B2 (en) | 2017-07-13 | 2022-10-25 | Upside Foods, Inc. | Compositions and methods for increasing the efficiency of cell cultures used for food production |
| US11713468B2 (en) | 2017-08-02 | 2023-08-01 | Dna Twopointo Inc. | DNA vectors and elements for sustained gene expression in eukaryotic cells |
| CN109988777A (zh) | 2017-12-29 | 2019-07-09 | 南京金斯瑞生物科技有限公司 | 谷氨酰胺合成酶基因以及应用 |
| CN110714057A (zh) | 2018-07-11 | 2020-01-21 | 成都金洛克生物技术有限公司 | 用于检测外源基因整合和定位的通用型fish探针及其应用 |
| CN109504709B (zh) | 2018-11-28 | 2020-07-24 | 上海安民生物技术有限公司 | 白蛋白启动子驱动的白蛋白表达载体 |
| AU2020225647B2 (en) | 2019-02-22 | 2025-06-05 | Smith & Nephew Asia Pacific Pte Limited | Combination electrosurgical and mechanical resection device |
| WO2020227206A1 (en) | 2019-05-07 | 2020-11-12 | Amgen Inc. | Vectors and expression systems for producing recombinant proteins |
-
2018
- 2018-05-24 EP EP23206416.2A patent/EP4295904A3/en active Pending
- 2018-05-24 US US16/616,884 patent/US12359184B2/en active Active
- 2018-05-24 CA CA3064352A patent/CA3064352A1/en active Pending
- 2018-05-24 MX MX2019014027A patent/MX2019014027A/es unknown
- 2018-05-24 KR KR1020257020185A patent/KR20250093434A/ko active Pending
- 2018-05-24 IL IL270817A patent/IL270817B2/en unknown
- 2018-05-24 KR KR1020197038087A patent/KR20200018488A/ko not_active Ceased
- 2018-05-24 BR BR112019024750A patent/BR112019024750A2/pt unknown
- 2018-05-24 WO PCT/GB2018/051415 patent/WO2018215780A1/en not_active Ceased
- 2018-05-24 CN CN202410244176.5A patent/CN118105471A/zh active Pending
- 2018-05-24 CN CN201880049768.4A patent/CN111093641A/zh active Pending
- 2018-05-24 JP JP2020515296A patent/JP2020520677A/ja active Pending
- 2018-05-24 EP EP18728717.2A patent/EP3630077A1/en active Pending
- 2018-05-24 EP EP22176864.1A patent/EP4119133A1/en active Pending
- 2018-05-24 AU AU2018272294A patent/AU2018272294B2/en active Active
-
2019
- 2019-11-22 MX MX2024002249A patent/MX2024002249A/es unknown
-
2022
- 2022-06-03 US US17/832,562 patent/US11932885B2/en active Active
- 2022-06-03 US US17/832,564 patent/US12338471B2/en active Active
-
2023
- 2023-03-10 JP JP2023038030A patent/JP7688926B2/ja active Active
- 2023-10-30 US US18/497,740 patent/US20240150746A1/en active Pending
-
2024
- 2024-02-20 AU AU2024201089A patent/AU2024201089B2/en active Active
- 2024-02-26 JP JP2024026784A patent/JP2024059833A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020520677A5 (enExample) | ||
| US11472842B2 (en) | Analogues of hepcidin mimetics with improved in vivo half lives | |
| US12234300B2 (en) | Conjugated hepcidin mimetics | |
| JP6525471B2 (ja) | ヘプシジン類似体及びその使用 | |
| CN102917726B (zh) | 干扰素类似物 | |
| JP2018522563A5 (enExample) | ||
| AU781678C (en) | Compositions and methods for counteracting effects of reactive oxygen species and free radicals | |
| JP2010518079A5 (enExample) | ||
| JP2017523959A (ja) | ヘプシジンおよびミニ−ヘプシジンアナログおよびその使用 | |
| JP2012529296A5 (enExample) | ||
| RU2012106150A (ru) | Вариантные формы уратоксидазы и их применение | |
| JP2013504589A5 (enExample) | ||
| TW201819398A (zh) | 治療性肽 | |
| JP2024520861A (ja) | 遺伝性ヘモクロマトーシスの治療のためのヘプシジン模倣体 | |
| JP6633523B2 (ja) | Ｐｓｄ−９５の二量体阻害剤脂肪酸誘導体 | |
| RU2014127270A (ru) | Аналог человеческого инсулина и его ацилированное производное | |
| CN110891612A (zh) | 蛋白质药物与p/a肽的缀合物 | |
| JP2014506450A5 (enExample) | ||
| US20230158100A1 (en) | Treatment of panx1 associates diseases | |
| JP2013529178A5 (enExample) | ||
| AU2021401137B2 (en) | Pharmaceutical composition of glp-1/glp-2 dual agonists | |
| RU2012157399A (ru) | Пептиды в качестве активных агентов для стабилизации биологических барьеров | |
| CA3200525A1 (en) | Pharmaceutical composition of glp-1/glp-2 dual agonists | |
| ES2387435B1 (es) | Uso de heptapéptidos para el control de la hipertensión | |
| CN108350033A (zh) | 端粒酶易位的肽抑制剂及其治疗用途 |